The decision by Synergen Inc. to drop development of Antril interleukin-1 receptor antagonist for sepsis will have significant consequences for the company. Whatever SYGN's ultimate fate, the decisions it must make point up the perils faced by companies dependent on one or two lead products.

SYGN is evaluating which operations will be dropped and will look at the possibility of the sale or merger of the company. (For results of the Antril study, see BioCentury Extra, July 18, 1994.)